Sepracor’s Brovana COPD Therapy Approved; Launch Planned For 2007
Sepracor's newly approved long-acting beta2-agonist for chronic obstructive pulmonary disease appears to have a slower onset of effect than Novartis/Schering-Plough's Foradil
You may also be interested in...
GlaxoSmithKline's asthma combination product Advair is included in an FDA advisory against first-line use of long-acting beta agonist bronchodilators despite an advisory committee review that suggested Advair was less risky than other products
Novartis will conduct holter heart monitoring in Foradil Aerolizer patients as a Phase IV commitment following the approval of formoterol for chronic obstructive pulmonary disease Sept. 25.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.